Hostname: page-component-8448b6f56d-tj2md Total loading time: 0 Render date: 2024-04-19T01:43:06.186Z Has data issue: false hasContentIssue false
  • English
  • Français

Depression and HIV Infection: Impact on Immune Function and Disease Progression

Published online by Cambridge University Press:  07 November 2014

Dean G. Cruess ,
John M. Petitto ,
Jane Leserman ,
Steven D. Douglas ,
David R. Gettes ,
Thomas R. Ten Have  and
Dwight L. Evans
Get access Rights & Permissions [Opens in a new window]

Abstract

Can psychological factors, such as depression, affect human immunodeficiency virus progession? HIV infection is viewed as a chronic illness in which those infected often confront a number of emotional challenges and physical health and disease-related issues. Over the past 20 years, there has been increasing evidence that depression and other mood-related disturbances are commonly observed among HIV-positive individuals. There is also mounting data showing that depressive symptoms might further impact upon specific elements of immune system functioning and influence quality of life and health status. This paper will highlight studies examining the prevalence of depression during HIV infection and review some of the evidence examining the impact of depressive symptoms on immune function and HIV disease progression.

Type
Review
Information
CNS Spectrums , Volume 8 , Issue 1: Neuropsychiatric HIV Infection , January 2003 , pp. 52 - 58
Copyright
Copyright © Cambridge University Press 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Cruess, DG, Leserman, J, Petitto, JM, et al.Psychosocial-immune relationships in HIV disease. Semin Clin Neuropsychiatry. 2001;6:241–251.CrossRefGoogle ScholarPubMed
2.Lyketsos, CG, Hutton, H, Fishman, M, Schwartz, J, Treisman G. Psychiatric morbidity on entry to an HIV primary care clinic. AIDS. 1996;10:1033–1039.CrossRefGoogle Scholar
3.Bing, EG, Burnam, MA, Longshore, D, et al.Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58:721–728.CrossRefGoogle ScholarPubMed
4.Hays, RD, Cunningham, WE, Sherbourne, CD, et al.Health-related quality of life in patients with human immunodeficiency virus infection in the United States: results from the HIV Cost and Services Utilization Study. Am J Med. 2000;108:714–722.CrossRefGoogle Scholar
5.Sherbourne, CD, Hays, RD, Fleishman, JA, et al.Impact of psychiatric conditions on health-related quality of life in persons with HIV infection. Am J Psychiatry. 2000;157:248–254.CrossRefGoogle ScholarPubMed
6.Regier, DA, Boyd, JH, Burke, JD, et al.One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites. Arch Gen Psychiatry. 1988;45:977–986.CrossRefGoogle ScholarPubMed
7.Robins, LN, Helzer, JE, Weissman, MM, et al.Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry. 1984;41:949–958.CrossRefGoogle ScholarPubMed
8.Atkinson, JH, Grant, I, Kennedy, CJ, et al.Prevalence of psychiatric disorders among men infected with human immunodeficiency virus: a controlled study. Arch Gen Psychiatry. 1988;45:859–864.CrossRefGoogle ScholarPubMed
9.Williams, JB, Rabkin, JG, Remien, RH, Gorman, JM, Ehrhardt, AA. Multidisciplinary baseline assessment of homosexual men with and without human immunodeficiency virus infection. II. Standardized clinical assessment of current and lifetime psychopathology. Arch Gen Psychiatry. 1991;48:124–130.CrossRefGoogle ScholarPubMed
10.Evans, DL, Perkins, DO. The clinical psychology of AIDS. Curr Opin Psychiatry. 1990;3:96–102.CrossRefGoogle Scholar
11.Rabkin, JG, Goetz, RR, Remien, RH, et al.Stability of mood despite HIV illness progression in a group of homosexual men. Am J Psychiatry. 1997;154:231–238.Google Scholar
12.Perkins, DO, Stern, RA, Golden, RN, et al.Mood disorders in HIV infection: prevalence and risk factors in a non-epicenter of the AIDS epidemic. Am J Psychiatry. 1994;151:233–236.Google Scholar
13.Lyketsos, CG, Hoover, DR, Guccione, M, et al.Changes in depressive symptoms as AIDS develops. The Multicenter AIDS Cohort Study. Am J Psychiatry. 1996;153:1430–1437.Google ScholarPubMed
14.Maj, M. Depressive syndromes and symptoms in subjects with human immunodeficiency virus (HIV) infection. Br J Psychiatry. 1996;30(suppl):117–122.CrossRefGoogle Scholar
15.Ciesla, JA, Roberts, JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry. 2001;158:725–730.CrossRefGoogle ScholarPubMed
16.Evans, DL, Mason, K, Bauer, R, Leserman, J, Petitto, J. Neuropsychiatric manifestations of HIV-1 infection and AIDS. In: Charney, D, Coyle, J, Davis, K, Nemeroff, C, eds. Psychopharmacology: The Fifth Generation of Progress. New York, NY: Raven Press; 2002:1281–1299Google Scholar
17.Blazer, DG, Kessler, RC, McGonagle, KA, Swartz, MS. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am J Psychiatry. 1994;151:979–986.Google Scholar
18.Goggin, K, Engelson, ES, Rabkin, JG, Kotler, DP. The relationship of mood, endocrine, and sexual disorders in human immunodeficiency virus positive (HIV+) women: an exploratory study. Psychosom Med. 1998;60:11–16.CrossRefGoogle ScholarPubMed
19.McDaniel, JS, Fowlie, E, Summerville, MB, Farber, EW, Cohen-Cole, SA. An assessment of rates of psychiatric morbidity and functioning in HIV disease. Gen Hosp Psychiatry. 1995;17:346–352.CrossRefGoogle ScholarPubMed
20.Boland, RJ, Moore, J, Schuman, P. The longitudinal course of depression in HIV-infected women [abstract]. Psychosomatics. 1999;40160.Google Scholar
21.Taylor, ER, Amodei, N, Mangos, R. The presence of psychiatric disorders in HIV-infected women. J Couns Dev. 1996;74:345–351.CrossRefGoogle Scholar
22.Ickovics, JR, Hamburger, ME, Vlahov, D, et al.Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA. 2001;285:1466–1474.CrossRefGoogle ScholarPubMed
23.Moore, J, Schuman, P, Schoenbaum, E, et al.Severe adverse life events and depressive symptoms among women with, or at risk for, HIV infection in four cities in the United States of America. AIDS. 1999;13:2459–2468.CrossRefGoogle ScholarPubMed
24.Smith, DK, Moore, JS, Warren, D, et al.The design, participants, and selected early findings of the HIV Epidemiology Research Study. In: O'Leary, A, Jemott, LS, eds. Women and AIDS: Coping and Care. New York, NY: Plenum Press; 1996:185–206.Google Scholar
25.Morrison, MF, Petitto, JM, Ten Have, T, et al.Depressive and anxiety disorders in women with HIV infection. Am J Psychiatry. 2002;159:789–796.CrossRefGoogle ScholarPubMed
26.Evans, DL, Leserman, J, Pederson, CA, et al.Immune correlates of stress and depression. Psychopharmacol Bull. 1989;25:319–324.Google ScholarPubMed
27.Stein, M, Miller, AH, Trestman, RL. Depression, the immune system and health and illness. Arch Gen Psych. 1991;48:171–177.CrossRefGoogle ScholarPubMed
28.Reichlin, S. Mechanisms of disease: neuroendocrine-immune interactions. N Engl J Med. 1993;239:1246–1253.Google Scholar
29.Evans, DL, Folds, JD, Petitto, JM, et al.Circulating natural killer cell phenotypes in men and women with major depression. Arch Gen Psych. 1992;49:388–395.CrossRefGoogle ScholarPubMed
30.Herbert, T, Cohen, S. Depression and immunity: a meta-analytic review. Psychol Bull. 1993;113:472–486.CrossRefGoogle ScholarPubMed
31.Weisse, CS. Depression and immunocompetence: a review of the literature. Psychol Bull. 1992;111:475–489.CrossRefGoogle ScholarPubMed
32.Evans, DL, Leserman, J, Perkins, DO, et al.Stress-associated reductions of cytotoxic T lymphocytes and natural killer cells in symptomatic HIV infection. Am J Psychiatry. 1995;152:543–550.Google Scholar
33.Leserman, J, Petitto, JM, Perkins, DO, et al.Severe stress, depressive symptoms, and changes in lymphocyte subsets in human immunodeficiency virus-infected men: a 2-year follow-up study. Arch Gen Psychiatry. 1997;54:279–285.CrossRefGoogle Scholar
34.Burack, JH, Barrett, DC, Stall, RD, et al.Depressive symptoms and CD4 lymphocyte decline among HIV-infected men. JAMA. 1993;270:2568–2573.CrossRefGoogle ScholarPubMed
35.Kemeny, ME, Weiner, H, Taylor, SE, et al.Repeated bereavement, depressed mood, and immune parameters in HIV seropositive and seronegative gay men. Health Psychol. 1994;13:14–24.CrossRefGoogle ScholarPubMed
36.Rabkin, JG, Williams, JB, Remien, RH, et al.Depression, distress, lymphocyte subsets, and human immunodeficiency virus symptoms on two occasions in HIV-positive homosexual men. Arch Gen Psychiatry. 1991;48:111–119.CrossRefGoogle ScholarPubMed
37.Perry, S, Fishman, B, Jacobsberg, L, Frances, A. Relationships over 1 year between lymphocyte subsets and psychosocial variables among adults with infection by human immunodeficiency virus. Arch Gen Psychiatry. 1992;49:396–401.CrossRefGoogle ScholarPubMed
38.Lyketsos, CG, Hoover, DR, Guccione, M, et al.Depressive symptoms as predictors of medical outcomes in HIV infection. JAMA. 1993;270:2563–2567.CrossRefGoogle ScholarPubMed
39.Zorrilla, EP, McKay, JR, Luborsky, L, Schmidt, K. Relation of stressors and depressive symptoms to clinical progression of viral illness. Am J Psychiatry. 1996;153:626–635.Google ScholarPubMed
40.Barrett, DC, Chesney, MA, Burack, JH, et al.Depression and CD4 decline [letter]. JAMA. 1994;2711743.Google Scholar
41.Mayne, TJ, Vittinghoff, E, Chesney, MA, Barrett, DC, Coates, TJ. Depressive affect and survival among gay and bisexual men infected with HIV. Arch Intern Med. 1996;156:2233–2238.CrossRefGoogle ScholarPubMed
42.Page-Schaeffer, K, Delonenze, GN, Satariano, WA, Winkelstein, W. Comorbidity and survival in HIV-infected men in the San Francisco Men's Health Survey. Ann Epidemiol. 1996;6:420–430.CrossRefGoogle Scholar
43.Lyketsos, CG, Hoover, DR, Guccione, M. Depression and survival among HIV-infected persons. JAMA. 1996;275:35–36.CrossRefGoogle ScholarPubMed
44.Spiegel, D, Kraemer, HC, Bloom, JR, Gottheil, E. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet. 1989;2:888–891.CrossRefGoogle ScholarPubMed
45.Ramirez, AJ, Craig, KJT, Watson, JP, et al.Stress and relapse of breast cancer. BMJ. 1989;298:291–293.CrossRefGoogle ScholarPubMed
46.Frasure-Smith, N, Lesperance, F, Talajic, M. Depression following myocardial infarction: impact on 6-month survival. JAMA. 1993;270:1819–1825.CrossRefGoogle ScholarPubMed
47.Frasure-Smith, N, Lesperance, F, Talajic, M. Depression and 18-month prognosis after myocardial infarction. Circulation. 1995;91:999–1005.CrossRefGoogle ScholarPubMed
48.Fawzy, FI, Fawzy, NW, Hyun, CS, et al.Malignant melanoma. Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch Gen Psychiatry. 1993;50:681–689.CrossRefGoogle ScholarPubMed
49.Musselman, DL, Evans, DL, Nemeroff, CB. The relationship of depression to cardiovascular disease: epidemiology, biology and treatment. Arch Gen Psychiatry. 1998;55:580–592.CrossRefGoogle ScholarPubMed
50.Schulz, R, Beach, SR. Caregiving as a risk factor for mortality: the Caregiver Health Effects Study. JAMA. 1999;2823:2215–2219.CrossRefGoogle Scholar
51.Faller, H, Bulzebruck, H, Drings, P, Lang, H. Coping, distress, and survival among patients with lung cancer. Arch Gen Psychiatry. 1999;55:756–762.CrossRefGoogle Scholar
52.Evans, DL, Leserman, J, Perkins, DO, et al.Severe life stress as a predictor of early disease progression in HIV infection. Am J Psychiatry. 1997;154:630–634.Google ScholarPubMed
53.Leserman, J, Jackson, ED, Petitto, JM, et al.Progression to AIDS: the effects of stress, depressive symptoms, and social support. Psychosom Med. 1999;61:397–406.CrossRefGoogle ScholarPubMed
54.Evans, DL, Ten Have, T, Douglas, SD, et al.Depression in women with HIV-infection is associated with viral load, CD8 T cells and natural killer lymphocytes. Am J Psychiatry. 2002;159:1752–1759.CrossRefGoogle Scholar
55.Leserman, J, Petitto, JM, Golden, RN, et al.The impact of stress, social support, coping and cortisol on progression to AIDS. Am J Psychiatry. 2000;157:1221–1228.CrossRefGoogle ScholarPubMed
56.Leserman, J, Petitto, JM, Gu, H, et al.Progression to AIDS, a clinical AIDS condition, and mortality: psychosocial and psychological predictors. Psychol Med. 2002;32:1059–1073.CrossRefGoogle Scholar
57.Evans, DL, Ten Have, T, Douglas, SD, et al.Association of depression with viral load, CD8 T lymphocytes, and natural killer cells in women with HIV infection. Am J Psychiatry. 2002;159:1752–1759.CrossRefGoogle ScholarPubMed
58.Maes, M. Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry. 1995;19:11–38.CrossRefGoogle ScholarPubMed
59.Levy, JA, Mackewicz, CE, Barker, E. Controlling HIV pathogenesis: the role of the noncytotoxic anti-HIV response of CD8+ T cells. Immunol Today. 1996;17:217–224.CrossRefGoogle ScholarPubMed
60.Chehimi, J, Starr, SE, Frank, I, et al.Natural killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from both health donors and human immunodeficiency virus-infected patients. J Exp Med. 1992;175:789–796.CrossRefGoogle Scholar
61.Whiteside, TL, Herberman, RB. Role of human natural killer cells in health and disease. Clin Diagn Lab Immunol. 1994;1:125–133.CrossRefGoogle ScholarPubMed
62.Oliva, A, Kinter, AL, Vaccarezza, M, et al.Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. J Clin Invest. 1998;102:223–231.CrossRefGoogle ScholarPubMed
63.Jassoy, C, Harrer, T, Rosenthal, T, et al.Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes release gamma interferon, tumor necrosis factor alpha (TNFα), and TNFß when they encounter their target antigens. J Viro. 1993;67:2844–2852.CrossRefGoogle Scholar
64.Ho, HN, Hultin, LE, Mitsuyasu, RT, et al.Circulating HIV-specific CD8+ cytotoxic T cells express CD38 and HLA-DR antigens. J Immunol. 1993;150:3070–3079.CrossRefGoogle ScholarPubMed
65.Fauci, AS, Pantaleo, G, Stanley, S, Weissman, D. Immunopathogenic mechanisms of HIV infection. Ann Intern Med. 1996;124:654–663.CrossRefGoogle ScholarPubMed
66.Ferbas, J. Perspectives on the role of CD8+ cell suppressor factors and cytotoxic T lymphocytes during HIV infection. AIDS Res Hum Retroviruses. 1998;14(suppl 2):S153–S160.Google ScholarPubMed
67.Greenberg, P, Riddell, S. Deficient cellular immunity-finding and fixing the defects. Science. 1999;285:546–551.CrossRefGoogle ScholarPubMed
68.Famularo, G, Moretti, S, Marcellini, S, Nucera E, DeSimone, C. CD8 lymphocytes in HIV infection: helpful and harmful. J Clin Lab Immunol. 1997;49:15–32.Google ScholarPubMed
69.Perrit, D, Sesok-Pizzini, DA, Schretzenmair, R, et al.C1.7 antigen expression on CD8+ T cells is activation dependent: increased proportion of C1.7+CD8+ T cells in HIV-1 infected patients with progressing disease. J Immunol. 1999;162:7563–7568.CrossRefGoogle Scholar
70.Gea-Banacloche, JC, Migueles, SA, Martino, L, et al.Maintenance of large numbers of virus-specific CD8+ T cells in HIV-infected progressors and long-term non-progressors. J Immunol. 2000;165:1082–1092.CrossRefGoogle Scholar
71.Gamberg, JC, Bowmer, MI, Trahey, JC, et al.Functional and genetic integrity of the CD8 T-cell repertoire in advanced HIV infection. AIDS. 1999;13:2043–2053.CrossRefGoogle ScholarPubMed
72.Levy, JA. The importance of the innate immune system in controlling HIV infection and disease. Trends Immunol. 2001;22:312–316.CrossRefGoogle ScholarPubMed
73.Giorgi, JV, Hultin, LE, McKeating, JA, et al.Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis. 1999;179:859.CrossRefGoogle ScholarPubMed
74.Liu, Z, Cumberland, WG, Hultin, LE, et al.CD8+ T-lymphocytes activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J Acquir Immune Defic Syndr. 1998;18:332–340.CrossRefGoogle ScholarPubMed
75.Rabkin, JG, Rabkin, R, Harrison, W, Wagner, G. Effect of imipramine on mood and enumerative measures of status in depressed patients with HIV illness. Am J Psychiatry. 1994;151:516–523.Google ScholarPubMed
76.Elliott, AJ, Uldall, KK, Bergam, K, et al.Randomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive outpatients. Am J Psychiatry. 1998;155:367–372.Google ScholarPubMed
77.Zisook, S, Peterkin, J, Goggin, KJ, et al.Treatment of major depression in HIV-seropositive men. HIV Neurobehavioral Research Center Group. J Clin Psychiatry. 1998;59:217–224.CrossRefGoogle ScholarPubMed
78.Rabkin, JG, Wagner, GJ, Rabkin, R. Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial. Am J Psychiatry. 1999;156:101–107.CrossRefGoogle ScholarPubMed
79.Rabkin, JG, Harrison, WN. Effect of imipramine on depression and immune status in a sample of men with HIV infection. Am J Psychiatry. 1990;147:495–497.Google Scholar
80.Rabkin, JG, Rabkin, R, Wagner, G. Effects of fluoxetine on mood and immune status in depressed patients with HIV illness. J Clin Psychiatry. 1994;55:92–97.Google ScholarPubMed
81.Rabkin, JG, Wagner, G, Rabkin, R. Effects of sertraline on mood and immune status in patients with depression and HIV illness. J Clin Psychiatry. 1994;55:433–439.Google ScholarPubMed
82.Ferrando, SJ, Goldman, JD, Charaness, WE. Selective serotonin reuptake inhibitor treatment of depression in symptomatic HIV infection and AIDS: improvement in affective and somatic symptoms. Gen Hosp Psychiatry. 1997;19:89–97.CrossRefGoogle ScholarPubMed
83.Ferrando, SJ, Rabkin, JG, DeMoore, GM, Rabkin, RR. Antidepressant treatment of depression in HIV-seropositive women. J Clin Psychiatry. 1999;60:741–746.CrossRefGoogle ScholarPubMed
84.Irwin, M, Lacher, U, Caldwell, C. Depression and reduced natural killer cytotoxicity: a longitudinal study of depressed patients and control subjects. Psychol Med. 1992;22:1045–1050.CrossRefGoogle ScholarPubMed
85.Schleifer, SJ, Keller, SE, Bartlett, JA. Depression and immunity: clinical factors and therapeutic course. Psychiatry Res. 1999;85:63–69.CrossRefGoogle ScholarPubMed
86.Frank, MG, Hendricks, SE, Johnson, DR, Wieseler, JL, Burke, WJ. Antidepressants augment natural killer cell activity: in vivo and in vitro. Neuropsychobiology. 1999;39:18–24.CrossRefGoogle ScholarPubMed
87.Miller, GE, Cohen, S. Psychological interventions and the immune system: a meta-analytic review and critique. Health Psychol. 2001;30:47–63.CrossRefGoogle Scholar
88.Goodkin, K, Feaster, DJ, Asthana, D, et al.A bereavement support group intervention is longitudinally associated with salutary effects on the CD4 cell count and number of physician visits. Clin Diagn Lab Immunol. 1998;5:382–391.CrossRefGoogle ScholarPubMed
89.Gregerson, MB, Roberts, IM, Amiri, MM. Absorption and imagery locate immune response in the body. Biofeedback Self Regul. 1996;21:149–165.CrossRefGoogle ScholarPubMed
90.Hewson-Bower, B, Drummond, PD. Secretory immunoglobulin A increases during relaxation in children with and without recurrent upper respiratory tract infections. J Dev Behav Pediatr. 1996;17:311–316.CrossRefGoogle ScholarPubMed
91.Fawzy, FI, Kemeny, ME, Fawzy, NW, et al.A structured psychiatric intervention for cancer patients: changes over time in immunological measures. Arch Gen Psychiatry. 1990;47:729–738.CrossRefGoogle ScholarPubMed
92.Petrie, KJ, Booth, RJ, Pennebaker, JW, Davison, KP, Thomas, MG. Disclosure of trauma and immune response to a hepatitis B vaccination program. J Consult Clin Psychol. 1995;63:787–792.CrossRefGoogle ScholarPubMed